Collegium Pharmaceutical (COLL)

Executive Summary

Collegium Pharmaceutical is a commercial-stage biopharmaceutical company specializing in pain management and neuropsychiatry, with a focus on abuse-deterrent formulations. Its lead product, Xtampza ER (oxycodone), is approved for chronic pain and generates the majority of revenue. The company also has a pipeline that includes HLD200 for ADHD, but recent trials have been terminated, and earlier-stage programs are limited. Collegium's strategy centers on responsible opioid prescribing and expanding into neuropsychiatry, though near-term growth drivers remain dependent on Xtampza ER's market performance and potential label expansions. The company faces generic competition and pricing pressures, but maintains a solid balance sheet and ongoing efforts to diversify. Overall, Collegium is a niche player with a single approved product, limiting its upside until pipeline progress is demonstrated.

Upcoming Catalysts (preview)

• TBDPotential label expansion for Xtampza ER to include additional pain indications40% success
• Q2 2026New product launch from pipeline (e.g., non-opioid pain asset) partnership or acquisition30% success
• Q1 2026Positive earnings or guidance update due to market share gains50% success